{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:16:30Z","timestamp":1768220190110,"version":"3.49.0"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Scientific Research Program of Beijing Municipal Commission of Education","award":["KM201710025005"],"award-info":[{"award-number":["KM201710025005"]}]},{"name":"the Scientific Research and Innovation Program of Capital Medical University","award":["XSKY2024035"],"award-info":[{"award-number":["XSKY2024035"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer (OC), the third most common gynecologic malignancy, is characterized by high mortality largely driven by chemotherapy resistance, leading to recurrence and metastasis. Using transcriptomic data from GSE73935, we constructed a weighted gene co-expression network and identified eight hub genes (IGF1R, CDH2, PDGFRA, CDKN1A, SHC1, SPP1, CAV1 and FGF18) associated with cisplatin resistance, among which CDH2 emerged as the most clinically relevant candidate. CDH2 demonstrated moderate diagnostic potential (AUC = 0.792) and was markedly upregulated in cisplatin-resistant A2780\/CP70 cells. Independent validation using clinical single-cell RNA-seq data (GSE211956) confirmed its selective enrichment in resistant tumor cell subpopulations. Gene set enrichment analysis linked elevated CDH2 expression to p53 signaling, DNA replication, nucleotide excision repair, and Toll-like receptor pathways, with qPCR supporting upregulation of key downstream genes in resistant cells. Immune deconvolution further indicated that high CDH2 expression correlated with increased infiltration of NK cells, Tregs, macrophages, and neutrophils, and immunohistochemistry verified CDH2 overexpression in cisplatin-resistant tissues. In addition, virtual screening and drug sensitivity profiling identified several FDA-approved agents with potential relevance to CDH2-associated drug response. These findings indicate that CDH2 may serve as a candidate marker associated with cisplatin response in OC, and its association with immune cell infiltration provides further insight into mechanisms potentially underlying chemoresistance.<\/jats:p>","DOI":"10.3390\/ijms27020713","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:13:01Z","timestamp":1768209181000},"page":"713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated Analyses Identify CDH2 as a Hub Gene Associated with Cisplatin Resistance and Prognosis in Ovarian Cancer"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4866-2807","authenticated-orcid":false,"given":"Jun-Yi","family":"Xu","sequence":"first","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Qi","family":"Tian","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4835-2019","authenticated-orcid":false,"given":"Zi-Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Heng","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hang","family":"Chu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5755-7792","authenticated-orcid":false,"given":"Wei-Ning","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-3991","authenticated-orcid":false,"given":"Ya-Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.eclinm.2024.102983","article-title":"Worldwide patterns and trends in ovarian cancer incidence by histological subtype a population-based analysis from 1988 to 2017","volume":"79","author":"Wei","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin the first metal-based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, G., Yang, H., Wang, Y., and Qin, J. (2025). Ovarian cancer targeted therapy: Current landscape and future challenges. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1535235"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","article-title":"Therapeutic strategies to overcome cisplatin resistance in ovarian cancer","volume":"232","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ctrv.2016.09.003","article-title":"Role and therapeutic potential of cdk12 in human cancers","volume":"50","author":"Guffanti","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114603","DOI":"10.1016\/j.ejmech.2022.114603","article-title":"Current progress and novel strategies that target cdk12 for drug discovery","volume":"240","author":"Lei","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Deng, J., Bai, X., Feng, X., Ni, J., Beretov, J., Graham, P., and Li, Y. (2019). Inhibition of pi3k\/akt\/mtor signaling path- way alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5824-9"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Xie, W., Yu, J., Yin, Y., Zhang, X., Zheng, X., and Wang, X. (2022). Oct4 induces emt and promotes ovarian cancer progression by regulating the pi3k\/akt\/mtor pathway. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.876257"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Langfelder, P., and Horvath, S. (2008). Wgcna an r package for weighted correlation network analysis. BMC Bioinform., 9.","DOI":"10.1186\/1471-2105-9-559"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"24165","DOI":"10.1002\/jcla.24165","article-title":"Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer","volume":"36","author":"Wang","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106779","DOI":"10.1016\/j.compbiomed.2023.106779","article-title":"Identification of key genes in colorectal cancer diagnosis by co-expression analysis weighted gene co-expression network analysis","volume":"157","author":"Mortezapour","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18552","DOI":"10.1111\/jcmm.18552","article-title":"Identification of two key biomarkers cd93 and fgl2 associated with survival of acute myeloid leukaemia by weighted gene co-expression network analysis","volume":"28","author":"Han","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Quan, Q., Xiong, X., Wu, S., and Yu, M. (2021). Identification of immune-related key genes in ovarian cancer based on wgcna. Front. Genet., 15.","DOI":"10.3389\/fgene.2021.760225"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity the rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.virusres.2018.05.009","article-title":"A new era of virus bioinformatics","volume":"251","author":"Ibrahim","year":"2018","journal-title":"Virus Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature15736","article-title":"Pharmacogenomic agreement between two cancer cell line data sets","volume":"528","author":"Stransky","year":"2015","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"114811","DOI":"10.1016\/j.bcp.2021.114811","article-title":"Single-cell RNA sequencing and bioinformatics as tools to decipher cancer heterogenicity and mechanisms of drug resistance","volume":"195","author":"Rosati","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Peng, L., Deng, S., Li, J., Zhang, Y., and Zhang, L. (2025). Single-cell RNA sequencing in unraveling acquired resistance to egfr-tkis in non-small cell lung cancer: New perspectives. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041483"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3892\/or.2014.3468","article-title":"Microarray-based detection and expression analysis of extracellular matrix proteins in drug-resistant ovarian cancer cell lines","volume":"32","author":"Januchowski","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/nar\/gky311","article-title":"Genemania update 2018","volume":"46","author":"Franz","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Assidi, M. (2022). High n-cadherin protein expression in ovarian cancer predicts poor survival and triggers cell invasion. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.870820"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2013.12.004","article-title":"Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through akt\/\u03b2-catenin\/snail signaling pathway","volume":"723","author":"Wang","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.neo.2021.08.003","article-title":"STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma","volume":"23","author":"Morelli","year":"2021","journal-title":"Neoplasia"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Haslehurst, A.M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., and Weberpals, J. (2012). Emt transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-91"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"40865","DOI":"10.1038\/srep40865","article-title":"Release activity-dependent control of vesicle endocytosis by the synaptic adhesion molecule n-cadherin","volume":"7","author":"Dagar","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Loh, C.-Y., Chai, J.Y., Tang, T.F., Wong, W.F., Sethi, G., Shanmugam, M.K., Chong, P.P., and Looi, C.Y. (2019). The e-cadherin and n-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells, 8.","DOI":"10.3390\/cells8101118"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hui, L., Zhang, S., Dong, X., Tian, D., Cui, Z., and Qiu, X. (2013). Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062171"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/030089161309900608","article-title":"Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma","volume":"99","author":"Fan","year":"2013","journal-title":"Tumori J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/bjs.8980","article-title":"Expression of cell adhesion molecules and prognosis in breast cancer","volume":"100","author":"Saadatmand","year":"2013","journal-title":"J. Br. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"109011","DOI":"10.1016\/j.isci.2024.109011","article-title":"Nuclear translocation of cleaved pcdh9 impairs gastric cancer metastasis by downregulating cdh2 expression","volume":"27","author":"Zhang","year":"2024","journal-title":"Iscience"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Du, B., and Shim, J.S. (2016). Targeting epithelial\u2013mesenchymal transition (emt) to overcome drug resistance in cancer. Molecules, 21.","DOI":"10.3390\/molecules21070965"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Powell, L.C., Quintela, M., James, D.W., Onyido, E., Howard, D., Edwards, K., Turney, J.L., Morgan, C.R., Worthington, J., and Williams, N. (2025). Cisplatin resistance alters ovarian cancer spheroid formation and impacts peritoneal invasion. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1450407"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bahar, E., Kim, J.Y., Kim, H.S., and Yoon, H. (2020). Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207613"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of brca1-and brca2-related mutations on ovarian and breast cancer survival: A meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_40","first-page":"73","article-title":"Cisplatin induced apoptosis of ovarian cancer a2780s cells by activation of erk\/p53\/puma signals","volume":"33","author":"Song","year":"2018","journal-title":"Histol. Histopathol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wang, J.Q., Jeelall, Y.S., Ferguson, L.L., and Horikawa, K. (2014). Toll-like receptors and cancer: Myd88 mutation and inflammation. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00367"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101063","DOI":"10.1016\/j.gendis.2023.06.032","article-title":"Molecular mechanisms of cisplatin resistance in ovarian cancer","volume":"11","author":"Jiang","year":"2023","journal-title":"Genes Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2147\/OTT.S552516","article-title":"Targeting ANXA4 to Overcome Cisplatin Resistance in Ovarian Cancer: A Bioinformatics and in Vitro Study","volume":"18","author":"Wang","year":"2025","journal-title":"OncoTargets Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.62347\/SMSG9047","article-title":"Single-cell RNA sequencing in ovarian cancer: Revealing new perspectives in the tumor microenvironment","volume":"16","author":"Zhao","year":"2024","journal-title":"Am. J. Transl. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","article-title":"The gene expression omnibus database","volume":"Volume 1418","author":"Clough","year":"2016","journal-title":"Statistical Genomics: Methods and Protocols"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"Platinum resistant ovarian cancer what is it who to treat and how to measure benefit","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:15:30Z","timestamp":1768209330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27020713"],"URL":"https:\/\/doi.org\/10.3390\/ijms27020713","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]}}}